Linezolid

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
월요일, 3월 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 24, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
월요일, 3월 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

ACTG Announces Launch of Clinical Trial Evaluating Novel Treatment for Tuberculous Meningitis

Retrieved on: 
목요일, 12월 7, 2023
TBM, Infection, NIAID, Tuberculous meningitis, Research, Vanderbilt University, DRS, University of California, Mortality, Spinal cord, Ageing, Membrane, Brain, Pyrazinamide, Linezolid, UM1, Inflammation, University, HIV, Bangladesh Technical Education Board, Tuberculosis, University of North Carolina, ACTG, Rifampicin, Pharmaceutical industry

LOS ANGELES, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the IMAGINE-TBM study (Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM, also known as A5384). IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.

Key Points: 
  • IMAGINE-TBM is a phase 2, randomized, open-label trial comparing a six-month regimen of high-dose rifampicin, high-dose isoniazid, linezolid, and pyrazinamide to the nine-month standard-of-care regimen for the treatment of tuberculous meningitis.
  • Tuberculous meningitis is a life-threatening infectious disease that causes inflammation of the membranes that surround the brain and spinal cord.
  • Even with standard-of-care treatment, outcomes are poor, with high rates of mortality and chronic disability among those who survive.
  • ACTG is led by Dr. Currier and Joseph J. Eron, M.D., University of North Carolina (ACTG Vice-Chair).

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
월요일, 11월 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
월요일, 11월 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on: 
월요일, 8월 14, 2023
PVT, Partnership, TB Alliance, Public, TB, Linezolid, Miliary tuberculosis, Ministry of National Health Services, Regulation and Coordination, Medicine, Dauntless (video game), Government, Patient, Tuberculosis, Remington, WHO, Moxifloxacin, World Health Organization, Disease, Pharmaceutical industry

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points: 
  • Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
  • Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
  • "Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
  • The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on: 
월요일, 8월 14, 2023
PVT, Partnership, TB Alliance, Public, TB, Linezolid, Miliary tuberculosis, Ministry of National Health Services, Regulation and Coordination, Medicine, Dauntless (video game), Government, Patient, Tuberculosis, Remington, WHO, Moxifloxacin, World Health Organization, Disease, Pharmaceutical industry

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points: 
  • Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
  • Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
  • "Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
  • The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

Emergence of Multidrug-Resistant Strains Steers Global Tuberculosis Therapeutics Market Towards $2.99 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
목요일, 7월 20, 2023
Infectious Diseases, Hospitals, Pharmaceutical, Health, Route of administration, Tuberculosis, Therapy, Prevalence, Antimalarial medication, Dosage form, TB, Linezolid, World Health Organization, COVID-19, Miliary tuberculosis, Active, USD, Market, BCG, Incidence, Mass drug administration, Guideline, Patient, Mortality, WHO, Death, Moxifloxacin, Pharmaceutical industry

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.

Key Points: 
  • The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030.
  • The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis.
  • The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021.
  • Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
수요일, 7월 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

Retrieved on: 
월요일, 7월 18, 2022
Nausea, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Intermediary, Bacteria, Bacterial pneumonia, Cutis marmorata telangiectatica congenita, Diarrhea, GLOBE, Food, Urinary tract infection, Fosfomycin, Infection, Moxifloxacin, Marketing, Human, Linezolid, Pyelonephritis, NASDAQ, Tablet, Vomiting, COVID-19, Bronchopneumonia, Food and Drug Administration, Therapy, Merck, NPU, Pharmaceutical industry

Nabriva will be the exclusive supplier of XENLETA to Er-Kim.

Key Points: 
  • Nabriva will be the exclusive supplier of XENLETA to Er-Kim.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.